Postoperative [125I] seed brachytherapy in the treatment of acinic cell carcinoma of the parotid gland
详细信息 查看全文
- 作者：Ming-hui Mao PhD (1)
Dr. Jian-Guo Zhang B.S. Med (1)
Jie Zhang PhD (1)
Lei Zheng PhD (1)
Shu-ming Liu PhD (1)
Ming-wei Huang PhD (1)
Yan Shi PhD (1) - 关键词：[125I] seed brachytherapy ; Parotid gland ; Acinic cell carcinoma ; Recurrence ; Facial nerve ; [125I] ; Seed ; Brachytherapie ; Ohrspeicheldrüse ; Azinuszellkarzinom ; Rezidiv ; Nervus facialis
- 刊名：Strahlentherapie und Onkologie
- 出版年：2014
- 出版时间：October 2014
- 年：2014
- 卷：190
- 期：11
- 页码：1008-1014
- 全文大小：515 KB
- 参考文献：1. Godwin JT, Foote FW Jr, Frazell EL (1954) Acinic cell adenocarcinoma of the parotid gland; report of twenty-seven cases. Am J Pathol 30:465-77
2. Harish K (2004) Management of primary malignant epithelial parotid tumors. Surg Oncol 13:7-6 CrossRef
3. Stafford ND, Wilde A (1997) Parotid cancer. Surg Oncol 6:209-13 CrossRef
4. Spafford PD, Mintz DR, Hay J (1991) Acinic cell carcinoma of the salivary gland: review and management. J Otolaryngol 20:262-66
5. North CA, Lee DJ, Piantadosi S et al (1990) Carcinoma of the major salivary glands treated by surgery or surgery plus postoperative radiotherapy. Int J Radiat Oncol Biol Phys 18:1319-326 CrossRef
6. Bhide SA, Harrington KJ, Nutting CM (2007) Otological toxicity after postoperative radiotherapy for parotid tumors. Clin Oncol (R Coll Radiol) 19:77-2 CrossRef
7. Li Y, Taylor JMG, Ten Haken RK et al (2007) The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 67:660-69 CrossRef
8. Notani K, Yamazaki Y, Kitada H et al (2003) Management of mandibular osteoradionecrosis corresponding to the severity of osteoradionecrosis and the method of radiotherapy. Head Neck 25:181-86 CrossRef
9. Tribius S, Sommer J, Prosch C et al (2013) Xerostomia after radiotherapy. Strahlenther Onkol 189:216-22 CrossRef
10. Douglas JG, Koh WJ, Austin-Seymour M et al (2003) Treatment of salivary gland neoplasms with fast neutron radiotherapy. Arch Otolaryngol Head Neck Surg 129:944-48 CrossRef
11. Puthawala A, Nisar Syed A M, Gamie S et al (2001) Interstitial low-dose-rate brachytherapy as a salvage treatment for recurrent head-and-neck cancers: long-term results. Int J Radiat Oncol Biol Phys 51:354-62 CrossRef
12. Bron LP, O’Brien CJ (1997) Facial nerve function after parotidectomy. Arch Otolaryngol Head Neck Surg 123:1091-096 CrossRef
13. Cha W, Kim MS, Ahn JC et al (2011) Clinical analysis of acinic cell carcinoma in parotid gland. Clin Exp Otorhinolaryngol 4:188-92 CrossRef
14. Andreoli MT, Andreoli SM, Shrime MG et al (2012) Radiotherapy in parotid acinic cell carcinoma: does it have an impact on survival? Arch Otolaryngol Head Neck Surg 138:436-36
15. Zb?ren P, Schüpbach J, Nuyens M et al (2003) Carcinoma of the parotid gland. Am J Surg 186:57-2 CrossRef
16. Connor NP, Cohen SB, Kammer RE et al (2006) Impact of conventional radiotherapy on health-related quality of life and critical functions of the head and neck. Int J Radiat Oncol Biol Phys 65:1051-062 CrossRef
17. Jiang YL, Meng N, Wang JJ et al (2010) CT-guided iodine-125 seed permanent implantation for recurrent head and neck cancers. Radiat Oncol 5:68 CrossRef
18. Glaser MG, Leslie MD, Coles I et al (1995) Iodine seeds in the treatment of slowly proliferating tumors in the head and neck region. Clin Oncol (R Coll Radiol) 7:106-09 CrossRef
19. Vikram B, Hilaris BS, Anderson L et al (1983) Permanent iodine-125 implants in head and neck cancer. Cancer 51:1310-314 facial Surgery, Peking University School and Hospital of Stomatology, 100081, Beijing, P.R.China - ISSN：1439-099X
文摘
Background This retrospective study was undertaken to analyze data from patients receiving iodine-125 ([125I]) seed brachytherapy postoperatively for the treatment of acinic cell carcinoma (ACC) of the parotid gland along with the following risk factors: residual tumor, recurrent tumor, facial nerve invasion, positive resection margins, advanced tumor stage, or tumor spillage. Patients and methods Twenty-nine patients with ACC (17 females, 12 males; age range, 13-3 years; median age, 37.3 years) were included. Median follow-up was 58.2 months (range, 14-22 months). Patients received [125I] seed brachytherapy (median actuarial D90, 177?Gy) 3-1 days (median, 14 days) following surgery. Radioactivity was 18.5-3.3?MBq per seed, and the prescription dose was 80-20?Gy. Results The 3-, 5-, and 10-year rates of local control were 93.1, 88.7, and 88.7-, respectively; overall survival was 96.6, 92, and 92-; disease-free survival was 93.1, 88.4, and 88.4-; and freedom from distant metastasis was 96.6, 91.2, and 91.2-. Lymph node metastases were absent in all patients, although two patients died with distant metastases. Facial nerve recovery was quick, and no severe radiotherapy-related complications were noted. Recurrence history, local recurrence, and distant metastasis significantly affected overall survival. Conclusion Postoperative [125I] seed brachytherapy is effective in treating ACC and has minor complications. Patients with a history of recurrence showed poor prognosis and were more likely to experience disease recurrence and develop metastases.